How can Johnson & Johnson Innovation help you reach your goals? Johnson & Johnson Innovation (JJI) is supporting innovation in major life science clusters through the life science incubator, Johnson & Johnson Innovation, JLABS (JLABS), with the ultimate aim of enabling commercialization of new healthcare solutions for patients. We know what you, the innovator, need to get your science to patients. It is because of you that JJI created regional centers that host a team of science and transaction experts whose goal is to find high potential early-stage (pre-clinical proof-of-concept) innovation and form custom business solutions around it to help accelerate the science to the patient. The JJI team has broad deal-making capabilities with the flexibility to adapt the deal structures to the science.
On November 16, hear from Johnson & Johnson Innovation leaders as they provide an overview of J&J Innovation goals and mission, highlighting how J&J Innovation interacts with the entrepreneurial community through JLABS, JJDC, and other J&J Innovation initiatives.
Speakers will also be on hand to meet with a handful of applicants one-on-one after the presentation.
10:30 AM | Registration Opens and Networking
11:00 AM | Presentation and Q&A
12:00 PM | Networking Lunch
12:30-5:00 PM | One-on-one Meetings*
*Companies must have applied for a one-on-one meeting ahead of time and be approved. The application period ends on October 25th.
Anuk Das | Head, Scientific Innovation, Janssen Human Microbiome Institute read bio»
Tom Luby | Sr Director, New Ventures, Johnson & Johnson Innovation read bio»
Bob Radinsky | VP, Oncology Scientific Innovation, Janssen R&D, LLC read bio»
This event is presented in partnership with Mount Sinai Innovation Partners.
Presentation & Lunch
FREE | General Public
FREE | Mt Sinai Employees, Students, and Faculty
FREE | Onsite
Includes presentation, Q&A, and lunch. All attendees must register, regardless of one-on-one meeting status. Pre-registration to attend the presentation, Q&A, and lunch will remain open until noon on November 15th (or sold out).
FREE | Application
FREE | Accepted Companies
Companies must apply for a one-on-one meeting ahead of time. The one-on-one application period ends on October 25th. Your application will be reviewed and you will be notified of acceptance by email on November 7th. Acceptance of one-on-one meetings is not guaranteed as all applications must be approved.
About the Meet with... Series:
The purpose of the Meet with Series events sponsored by JLABS is to help start-up entrepreneurs, as well as the academic community, connect with potential partners, such as big pharma or other investment corporations, through one-on-one meetings. It is also a chance for the featured corporation to outline their specific business development goals and clarify what types of products or research they are interested in and how best to approach them to get the partnering process started. Past participants include the Wellcome Trust, Bill & Melinda Gates Foundation, MedImmune Ventures, NCI, Mercury Fund, DARPA's Biological Technologies Office, Correlation Ventures, Breakout Labs, New Enterprise Associates, Canaan Partners, Thomas McNerney & Partners, NCATS, NINDS, Johnson & Johnson Innovation, Poliwogg, California Institute for Regenerative Medicine, Astellas Venture Management, and OrbiMed.
Participating Representatives' Biographies:
Anuk Das, Ph.D. | Head, Scientific Innovation, Janssen Human Microbiome Institute, Janssen Research & Development
Anuk Das, Ph.D., is Head of Scientific Innovation in the newly created Janssen Human Microbiome Institute (JHMI). Anuk is responsible for developing and maintaining partnerships across a multitude of collaborators and stakeholders working closely with the Johnson & Johnson Innovation Centers to solidify JHMI’s industry leadership position in delivering microbiome healthcare solutions.
Anuk joined the Janssen Pharmaceutical Companies of Johnson & Johnson in 2001 and has since catalyzed the evaluation of emerging areas of research with promising scientific potential for the Immunology Therapeutic Area (TA). Following a successful record of program and functional leadership spanning several disease areas focused upon the discovery and development of potential new medicines, Anuk led External Research. In this role she delivered new areas of scientific research that shaped the Disease Area Stronghold (DAS) strategies for disease interception and prevention. Her work helped to establish a global network of external partners in academia and biotechnology for the Immunology TA and further drove investments in emerging areas of interest, including several ongoing projects focused on the microbiome. Most recently, Anuk served as Senior Director, Disease Integrative Biology (DIB), and launched the Immunology Exploratory Science Laboratory (I-ExSL) and Immunology Postdoctoral Program. As the founder of these groups, Anuk built productive scientific functions that leveraged human disease knowledge and the network pharmacology disease platform to establish new paradigms for identifying and validating novel therapeutic mechanisms.
Dr. Das obtained her BSc (Honors) at the University of Bath (UK) in Pharmacology and completed her PhD in Pharmacology at the National Heart & Lung Institute, University of London (UK) focused on allergic inflammatory mechanisms. She has co-authored over 50 scientific articles, patents and patent applications.
Connect with Anuk:
Thomas Luby, Ph.D. | Senior Director, New Ventures, Johnson & Johnson Innovation
Tom is Senior Director of New Ventures at Johnson & Johnson Innovation, Boston. He focuses primarily on cardiovascular & metabolic; infectious diseases and Vaccines; and neurobiology. Prior to joining the Johnson & Johnson Family of Companies, Tom was the Sr. Director of Research Ventures at Shire Human Genetic Therapies. In this position, Tom played a central role in the evaluation, diligence, and deal processes across a number of successful early-stage investments in the rare disease space. He was member of the BOD at Armagen Technologies, led the collaboration with Nimbus Discovery, and was instrumental in establishing and leading the alliance that Shire put in place with Atlas Venture. Prior to this, Tom held a variety of research and development roles in both start-up and mid-sized biotech. He has worked on multiple discovery through Phase II programs in infectious disease, oncology, immunotherapy, and monogenetic disorders. His experience includes pre-clinical development, early-stage portfolio oversight, licensing, due diligence, company formation, alliance management, and key opinion leader outreach. Tom received his BS in Biology from State University of New York, his Ph.D. in Immunology from Tufts University, and was a post-doctoral fellow in yeast genetics at Harvard School of Public Health.
Connect with Tom:
Robert Radinsky, Ph.D. | Vice President, Oncology Scientific Innovation, The Janssen Pharmaceutical Companies of Johnson & Johnson
Robert Radinsky, Ph.D. is Vice President, Scientific Innovation at Janssen Research & Development, LLC. He represents the Oncology Therapeutic Area in Johnson & Johnson Innovation, Boston. In this role, he is responsible for identifying and fostering innovation in the region that supports the Oncology Therapeutic Area strategies. Prior to this role, he led Discovery Research, Oncology, for Janssen. Robert has had a very successful oncology research career in both academics and industry. Prior to joining Janssen, he was Executive Director, Oncology Research at Amgen Inc., where he led groups at multiple research sites including Thousand Oaks, California, and Cambridge, Massachusetts. He was responsible, in part, for research and/or pharmacology for numerous active targeted therapeutic anti-cancer programs (protein, small molecule and nanotechnology modalities), culminating with multiple candidates in clinical trials and an approved drug for the treatment of colorectal carcinoma. Before joining the industry 14 years ago, Robert was on the faculty at The University of Texas MD Anderson Cancer Center in Houston, first serving as an American Cancer Society Postdoctoral Research Fellow in the Department of Cell Biology, and eventually becoming a tenured Associate Professor in the Department of Cancer Biology. He continued as an Adjunct Professor at the MD Anderson Cancer Center after joining the industry. Robert has published more than 130 peer-reviewed articles, holds multiple patents, and is a present/past member of numerous societies, including the American Association for Cancer Research, Board of Directors for the Metastasis Research Society, the American Association for the Advancement of Science, the Scientific Advisory Board and the Aspen Cancer Conference. He is an Editorial Member and/or ad hoc reviewer for more than 20 scientific journals and has served on review panels for a number of granting agencies, including the National Institutes of Health/National Cancer Institute, the Department of Defense Prostate and Breast Cancer Research Programs, and the Veterans Administration Merit Review Board. Robert earned his doctorate in Molecular Biology and Microbiology from Case Western Reserve University School of Medicine in Cleveland, Ohio.
Connect with Bob:
Icahn School of Medicine at Mount Sinai
Davis Auditorium - 2nd Floor
Hess Center for Science and Medicine
1470 Madison Avenue
New York, NY 10029
When & Where
JLABS, part of Johnson & Johnson Innovation, LLC, is a network of life science incubators providing emerging companies many of the advantages of being in a big company, without the capital investment. JLABS offers singular bench tops, modular wet lab units and office space on a short-term basis, allowing companies to pay only for the space they need, with an option to quickly expand when they have the resources to do so. Companies residing at JLABS also have access to core research labs hosting specialized capital equipment and shared administrative areas. JLABS is an open innovation model, and the agreement for space does not grant JLABS or Johnson & Johnson Innovation any stake or rights in the companies, nor will the companies have a guaranteed future affiliation with JLABS. The flagship facility is located in San Diego at Janssen's West Coast Research Center, and JLABS has now two established locations in San Francisco - one through a collaboration with the California Institute for Quantitative Biosciences (QB3) and a second standalone facility - one in Boston through a collaboration with Lab Central, one in Houston through a collaboration with TMC, and one in Toronto through a collaboration with MaRS. For more information please visit jlabs.jnjinnovation.com.